The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists.

van Baar, Michaël J B; van der Aart, Annemarie B; Hoogenberg, Klaas; Joles, Jaap A; Heerspink, Hiddo J L; van Raalte, Daniël H

van Baar, Michaël J B; van der Aart, Annemarie B; Hoogenberg, Klaas; Joles, Jaap A; Heerspink, Hiddo J L; van Raalte, Daniël H.

Afiliación

van Baar MJB; Department of Internal Medicine, Amsterdam University Medical Centers, VUMC, Amsterdam, The Netherlands.
van der Aart AB; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
Hoogenberg K; Department of Internal Medicine, Martini Hospital, Groningen, The Netherlands.
Joles JA; Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
van Raalte DH; Amsterdam University Medical Centers, VUMC, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Ther Adv Endocrinol Metab ; 10: 2042018819865398, 2019.

Article en En | MEDLINE | ID: mdl-31384419

Palabras clave

GLP-1 receptor agonists; albuminuria; blood pressure; diabetic kidney disease; incretin-based therapies

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ther Adv Endocrinol Metab Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google